Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PolyPid Ltd PYPD

Healthcare Biotechnology
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Recent & Breaking News (NDAQ:PYPD)

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

GlobeNewswire 5 days ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

GlobeNewswire 7 days ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

GlobeNewswire May 20, 2025

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

GlobeNewswire May 14, 2025

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

GlobeNewswire April 29, 2025

PolyPid to Participate in The Citizens Life Sciences Conference

GlobeNewswire April 22, 2025

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

GlobeNewswire March 11, 2025

PolyPid to Participate in the 37th Annual ROTH Conference

GlobeNewswire March 3, 2025

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

GlobeNewswire February 12, 2025

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire January 30, 2025

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

GlobeNewswire January 29, 2025

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

GlobeNewswire December 23, 2024

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

GlobeNewswire December 11, 2024

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

GlobeNewswire November 29, 2024

PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire November 13, 2024

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

GlobeNewswire November 7, 2024

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

GlobeNewswire October 30, 2024

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

GlobeNewswire October 21, 2024

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

GlobeNewswire October 1, 2024

PolyPid to Participate in Three Upcoming Fall Investor Conferences

GlobeNewswire September 3, 2024